Fol. Biol. 2003, 49, 69-73
https://doi.org/10.14712/fb2003049020069
Adjuvant Autologous Tumour Cell-Lysate Vaccine versus No Adjuvant Treatment in Patients with M0 Renal Cell Carcinoma after Radical Nephrectomy: 3-Year Interim Analysis of a German Multicentre Phase-III Trial
References
1. 1999) Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon alpha treatment with untreated control. Anticancer Res. 19, 1545-1548.
, R., Corvin, S., Handel, D., Hinke, A., Schmidt, D. (
2. 1994) Tumor antigens recognized by T lymphocytes. Rev. Immunol. Ann. 12, 337-365.
< , T., Cerottini, J. C., Van den Eynde, B., Van der Bruggen, P., Van Pel, A. (https://doi.org/10.1146/annurev.iy.12.040194.002005>
3. 1988) Prognostic factors in renal cell carcinoma. Eur. Urol. 115, 73-76.
< , M., Arbitani, W., Bassi, P. F., Pescatori, E., Pagano, F. (https://doi.org/10.1159/000473400>
4. 1993) Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J. Immunother. 14, 65-69.
< , R. O., Nayak, S. K., Beutel, L. (https://doi.org/10.1097/00002371-199307000-00009>
5. 1992) Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology 39, 122-129.
< , C. P., Awad, S. A., Gajewski, J. B., Belitsky, P., Lannon, S. G., Mack, F. G., Millard, O. H. (https://doi.org/10.1016/0090-4295(92)90267-Z>
6. 1999) Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-387.
< , R. A. (https://doi.org/10.1016/S0022-5347(01)61897-4>
7. 1973) The value of radiotherapy in the treatment of hypernephroma - a clinical trial. Br. J. Urol. 45, 258-269.
< , R. (https://doi.org/10.1111/j.1464-410X.1973.tb12152.x>
8. 1997) Urologic tumors in Germany. Urologe A 36, 143-150.
< , C. C., Wächter, W. C., Fuentecilla Perez, E., Miller, J., Weidner, W., Dudeck, J. (https://doi.org/10.1007/s001200050080>
9. 1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77, 2560-2566.
< , E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D., Santarosa, M., Sacco, C., Talamini, R. (https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P>
10. 1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
< , B., Zeier, K., Daniels, B., Cronin, K., Bennerji, R., Gilboa, E. (https://doi.org/10.1084/jem.172.4.1217>
11. 1990) Radical extensive surgery for renal cell carcinoma: longterm results and prognostic factors. J. Urol. 143, 468-474.
< , L., Gilberti, C., Martorana, G., Rovida, S. (https://doi.org/10.1016/S0022-5347(17)39992-5>
12. 1995) Renal cell carcinoma: tumor size, stage and survival. J. Urol. 153, 901-903.
< , P. D., Vogelzang, N. J., Fremgen, A. M., Chmiel, J. S., Sylvester, J. L., Sener, S. F., Imperato, J. P. (https://doi.org/10.1016/S0022-5347(01)67599-2>
13. 1998) Adjuvant therapy of renal cell carcinoma (RCC) with a pure-celllysate autologous tumor vaccine (aTm): a 3-year-followup-analysis. Proc. Am. Ass. Cancer Res. 39, 367.
, A. J. W., Hockertz, S. W., Repmann, R., Richter, A., Ulbrich, C., Groflmann, A. (
14. 1990) Evaluation of the new tumor, nodes and metastases classification of renal carcinoma. J. Urol. 144, 238-242.
< , P., Schrott, K. M. (https://doi.org/10.1016/S0022-5347(17)39420-X>
15. 1999) The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in factors in pT3N0M0 renal cell carcinoma. Anticancer Res. 19, 5593-5597.
, S. H., Chang, S. G., Kim, J. I. (
16. 1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int. J. Radiat. Oncol. Biol. Physiol. 13, 665-672.
< , M., Frederiksen, P. L., Engelholm, S. A. (https://doi.org/10.1016/0360-3016(87)90283-5>
17. 1995) Tumor cell vaccination for treatment of renal cell carcinoma. Urologe A 34, 204-207.
, M., Oberneder, R. (
18. 1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163-1167.
< , D. A., Slaton, J. W., Swanson, D. A., Dinney, C. P. (https://doi.org/10.1016/S0022-5347(01)63541-9>
19. 1998) The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45, 380-383.
, R., Zarzycka, M., Kulinska, G., Windorbska, W. (
20. 1981) Renal cell carcinoma: long-term survival and late recurrence. J. Urol. 126, 17-23.
< , D. W., Segura, J. W., DeWeerd, J. H. (https://doi.org/10.1016/S0022-5347(17)54359-1>
21. 1995) Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT23N0M0 renal cell carcinoma? J. Chemother. 7, 240-245.
< , R., Muscas, G., Solinas, A., Melis, M., Ionta, M. T., Massidda, B., Usai, E. (https://doi.org/10.1179/joc.1995.7.3.240>
22. 1996) Renal-cell carcinoma. New Engl. J. Med. 335, 865-875.
< , R. J., Bander, N. H., Nanus, D. M. (https://doi.org/10.1056/NEJM199609193351207>
23. 2000) Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417.
< , R. J., Russo, P. (https://doi.org/10.1016/S0022-5347(05)67889-5>
24. 2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19, 425-431.
< , G., Piva, L., Colavita, M., Ferri, S., Artusi, R., Boracchi, P., Parmiani, G., Marubini, E. (https://doi.org/10.1200/JCO.2001.19.2.425>
25. 1995) Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. Urologe A 34, 215-220.
, S., Thiele, R., Staehler, G., Drehmer, L., Lohrke, H., Schirrmacher, V. (
26. 1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjunct local and systemic therapy. J. Clin. Oncol. 12, 206-212.
< , R. A., Zelefsky, M. J., Gaynor, J. J., Fuks, Z. (https://doi.org/10.1200/JCO.1994.12.1.206>
27. 1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85-96.
< , H. G. (https://doi.org/10.1016/0952-7915(95)80033-6>
28. 1997) Adjuvant therapy of renal cell carcinoma with active-specificimmunotherapy (ASI) using autologous tumor vaccine. Anticancer Res. 17, 2879-2882.
, R., Wagner, S., Richter, A. (
29. 1969) The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101, 297-301.
< , C. J., Churchill, B. M., Anderson, W. (https://doi.org/10.1016/S0022-5347(17)62331-0>
30. 1995) A new protocol for the followup of renal cell carcinoma based on pathological stage. J. Urol. 154, 28-31.
< , D. S., Seftel, A. D., Resnick, M. I. (https://doi.org/10.1016/S0022-5347(01)67215-X>
31. 1995) Surface antigens in renal cell carcinoma: presentation of MHC Irestricted self peptides. Akt. Urol. 26, 45-46.
< , S., Pomer, S., Rammensee, H. G. (https://doi.org/10.1055/s-2008-1057856>
32. 1989) Prognostic parameters in renal cell carcinoma - a new approach. Eur. Urol. 16, 416-422.
< , S., Thoenes, W., Jacobi, G. H., Lippold, R. (https://doi.org/10.1159/000471633>
33. 2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J. Urol. 163, 1090-1095.
< , K. H., Shvarts, O., Smith, R. B., Figlin, R. A., deKernion, J. B., Belldegrun, A. (https://doi.org/10.1016/S0022-5347(05)67699-9>
34. Wittekind, C., Wagner, G. (1997) TNM Classification of malignant tumors. 5th edition, Springer, Berlin/Heidelberg. http://www.seer.cancer.gov
35. 1995) Chemotherapy for advanced renal cell carcinoma 1983-1993. Semin. Oncol. 22, 42-60.
, A., Bassam, A. R., Petrylak, D. (